Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Delta-24-RGD by convection-enhanced delivery for recurrent glioblastoma
NL-OMON35590Phase 2Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Jun 2010
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of Ad5-D24RGD in glioblastoma (GBM), sponsored by Erasmus MC. Started Jun 2010; status: active, not recruiting.
02
Drugs
Ad5-D24RGD
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NL-OMON35590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35590.